U.S. markets open in 7 hours 56 minutes

Sosei Group Corporation (4565.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
1,911.00-2.00 (-0.10%)
As of 2:12PM JST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1,913.00
Open1,915.00
Bid1,909.00 x 0
Ask1,910.00 x 0
Day's Range1,894.00 - 1,933.00
52 Week Range1,238.00 - 2,104.00
Volume193,000
Avg. Volume633,708
Market Cap154.298B
Beta (5Y Monthly)1.56
PE Ratio (TTM)102.80
EPS (TTM)18.59
Earnings DateMay 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 27, 2015
1y Target Est2,646.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
      PR Newswire

      Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

      Sosei Group Corporation ("the Company") (TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ("Formosa") has dosed the first patient in a 370-patient randomized Phase 3 clinical trial of APP13007 in the United States (ClinicalTrials.gov Identifier: NCT04739709). APP13007 is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery. The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa.

    • Sosei Heptares spin-off company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals
      PR Newswire

      Sosei Heptares spin-off company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals

      Sosei Group Corporation ("the Company") (TSE: 4565) notes the announcement today from Centessa Pharmaceuticals ("Centessa") about its launch as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. In conjunction with its launch, Centessa has completed the merger of 10 private biotech companies ("Centessa Subsidiaries") that will each continue to develop its assets with oversight from the Centessa management team.

    • Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020
      PR Newswire

      Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020

      Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2020. The full report can be accessed by clicking here.